ClinicalTrials.gg
CompletedNCT07368712Updated Nov 2, 2026

A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney Function

An interventional study of No investigational study intervention in Acute Kidney Injury, Renal Insufficiency, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Bayer · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Acute Kidney Injury with a site in Germany — 21 open to participants now, 24 under way, 1 of them phase 3. Acute Kidney Injury · Germany.

Enrollment
51st of 62
33 · median 112
Started
2026
with 6 others
No phase
39 of 109
10 open now
Registered
101st of 109
by date

Among the 109 studies in Acute Kidney Injury with a site in Germany, this one is the 51st largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, and was the 101st registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 109 studies in Acute Kidney Injury with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Acute Kidney Injury with a site in Germany, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate how reliable a test assessing the renal functional reserve (RFR) and the maximum glomerular filtration rate (maxGFR) are. MaxGFR and RFR assessments are repeated twice at 1-month intervals. If precise, this test may improve the measure of kidney function and be useful in future studies for people with chronic kidney problems.

To do this, the researchers will collect and analyze information about kidney function from up to 50 adults, including healthy people and people with stable kidney problems. Each person will come to the study center for a screening visit and then three study days, each about a month apart. On each study day, participants will have blood and urine samples taken before and after drinking a protein shake. The tests will measure things like creatinine, cystatin C, and other markers in the blood and urine to see how the kidneys are working. The study will also record basic health information, weight, blood pressure, and any medicines being taken.

The study will last about 2 to 2.5 months for each participant.

03

Conditions studied

  • Acute Kidney Injury, Renal Insufficiency
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 75 years of age inclusive, at the time of signing the ICF.
  • Stable medical condition defined as no new drug or other treatment prescribed for a chronic condition within 60 days prior to Study Day 1.
  • Body weight between 50 and 100 kg.
  • Female Participants: A participant is eligible to participate if not pregnant or breastfeeding. If a urine test cannot be confirmed as negative at screening (e.g., an ambiguous result), the participant must be excluded from participation.

Exclusion criteria

Exclusion Criteria:

  • Recent surgical intervention within 60 days prior to Study Day 1.
  • New clinical diagnosis established within 60 days prior to Study Day 1.
  • New drug prescription within 60 days prior to Study Day 1.
  • Relevant change in severity of any medical condition within 60 days prior to Study Day 1, e.g. disease flare.
  • Known congenital amino acid metabolism disorders.
  • Severe to milk products.
  • Known liver cirrhosis.
  • Regular use of non-steroidal anti-inflammatory drugs (NSAIDs).
  • Impaired kidney function with \<30 mL/min/1.73m2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Other
    Group 1

    Other: No investigational study intervention

Interventions

  • OtherNo investigational study intervention

    The study does not involve the administration of any study intervention, investigational medicinal product, or device. Participants will undergo blood collection and urine sampling both before and after consuming a high-protein meal.

06

What researchers measure

Primary outcomes

  1. Maximun kidneyfunction determined by measurement of creatinine clearance (mGFRCR)

    Time frame: Day 1, 28 and 56

  2. Renal functional reserve by measurement of creatinine clearance (mGFRCR)

    Time frame: Day 1, 28 and 56

Secondary outcomes

  1. Maximum kidney function and renal functional reserve derived from serum creatinine-based eGFR (eGFRSCR)

    Time frame: Day 1, 28 and 56

  2. Maximum kidney function and renal functional reserve derived from serum cystatin C-based eGFR (eGFRCYS)

    Time frame: Day 1, 28 and 56

  3. Maximum kidney function and renal functional reserve derived from serum creatinine-based and serum cystatin C-based eGFR (eGFRSCR-CYS)

    Time frame: Day 1, 28 and 56

  4. Maximum creatinine clearance and renal functional reserve derived from plasma PENK-based eGFR (eGFRPENK)

    Time frame: Day 1, 28 and 56

07

Study locations

1 site
  • Bayer AG - Occupational Health Services
    Berlin, 13353, Germany
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Sep 2026, 8 months.

Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 8 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Feb 2027 → Sep 2026 and completion Feb 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2026
First posted
Jan 27, 2026
StartActual
Jan 6, 2026
Primary completionActual
Sep 9, 2026was Feb 2027
CompletionActual
Sep 9, 2026was Feb 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Germany)
  • Bayer AG - Occupational Health Services · Berlin, Germany
  • Bayer AG - Occupational Health Services · Berlin, Germany
Show 2 removed
  • Bayer AG - Occupational Health Services · Berlin, Germany
  • Bayer AG - Occupational Health Services · Berlin, Germany
across 2 updates, Oct 14, 2026 – Nov 2, 2026
Primary completion
Feb 19, 2027→Sep 9, 2026 (actual)
Nov 2, 2026
Study completion
Feb 19, 2027→Sep 9, 2026 (actual)
Nov 2, 2026
Enrollment
50→33 (actual)
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Bayer AG - Occupational Health Services · Berlin, Germany
    Show 1 removed
    • Bayer AG - Occupational Health Services · Berlin, Germany
    Primary completion Feb 19, 2027→Sep 9, 2026 (now actual)
    Study completion Feb 19, 2027→Sep 9, 2026 (now actual)
    Enrollment 58 (estimated)→33 (actual)
    + 2 other changes: verification date and contact details
  2. Oct 14, 2026
    1 site added, 1 site removed
    Show site
    • Bayer AG - Occupational Health Services · Berlin, Germany
    Show 1 removed
    • Bayer AG - Occupational Health Services · Berlin, Germany
    Enrollment 50→58
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07368712
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 27, 2026
Start date
Jan 6, 2026
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion